Novartis 2Q Revenues: $12.2 billion (-2%) 2Q Earnings: $2.0 billion (+10%) YTD Revenues: $23.8 billion (-1%) YTD Earnings: $3.6 billion (-5%) Comments: Innovative Medicines sales were $8.3 billion (-1%) in the second quarter, with growth driven by Cosentyx ($490 million, +90% cc), Entresto ($110 million +240% cc), Promacta/Revolade ($210 million, +35% cc), Tafinlar + Mekinist (USD 216 million, +28% cc), Jakavi ($186 million, +32% cc), and Gilenya $837 million, +5% cc). Generic competition h...